Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$120.27 USD

120.27
1,329,241

-4.06 (-3.27%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $120.22 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -15.65% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

by Zacks Equity Research

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe

by Zacks Equity Research

Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

by Zacks Equity Research

Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -45.22% and 7.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

by Zacks Equity Research

Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.

Shaun Pruitt headshot

Top Medical Stocks to Buy for Growth & Performance

by Shaun Pruitt

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.